Cadonilimab, the first bispecific immune checkpoint inhibitor approved globally, simultaneously targets PD-1 and CTLA-4, enhancing anti-tumor efficacy through dual-pathway blockade (18). This evidence concerns the gene PDCD1 and neoplasm.